COST-EFFECTIVENESS OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS

被引：0
|
作者：
Olasupo, O. [1 ]
Matino, D. [1 ]
Iorio, A. [1 ]
Blackhouse, G. [1 ]
Xie, F. [1 ]
Tarride, J. E. [1 ]
机构：
[1] McMaster Univ, Hamilton, ON, Canada
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE476
引用
收藏
页码：S428 / S428
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness of emicizumab prophylaxis for haemophilia A with inhibitors: an adaptive health technology assessment for the Indian setting
    Kar, Sitanshu Sekhar
    Sivanantham, Parthibane
    Ravel, Vanessa
    Mehndiratta, Abha
    Tyagi, Kirti
    Ollendorf, Daniel A.
    BMJ EVIDENCE-BASED MEDICINE, 2024,
  • [32] IMPACT OF SWITCHING PROPHYLAXIS TREATMENT FROM FACTOR VIII TO EMICIZUMAB IN HEMOPHILIA A PATIENTS WITHOUT INHIBITORS
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Robert G.
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : E34 - E34
  • [33] RESOURCE CONSUMPTION ANALYSIS IN PATIENTS WITH HEMOPHILIA A WITHOUT INHIBITORS ON PROPHYLAXIS WITH FVIII BEFORE SWITCHING TO EMICIZUMAB
    Giacomini, E.
    Leogrande, M.
    Motta, L.
    Tempre, R.
    Bendinelli, S.
    Degli Esposti, L.
    VALUE IN HEALTH, 2023, 26 (12) : S69 - S69
  • [34] Impact of switching prophylaxis treatment from factor VIII to emicizumab in hemophilia A patients without inhibitors
    Escobar, Miguel
    Agrawal, Neha
    Chatterjee, Sagnik
    Bhattacharya, Swastik
    Caicedo, Jorge
    Bullano, Michael
    Schultz, Bob G. G.
    JOURNAL OF MEDICAL ECONOMICS, 2023, 26 (01) : 574 - 580
  • [35] The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors
    Agboola, Foluso
    Rind, David M.
    Walton, Surrey M.
    Herron-Smith, Serina
    Quach, Danny
    Pearson, Steven D.
    JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (05): : 667 - 673
  • [36] A BOY WITH HEMOPHILIA A WITHOUT INHIBITORS IN PROPHYLAXIS WITH EMICIZUMAB IN PORTUGAL: IS HE THE FIRST OF MANY?
    Campanico, S.
    Catarino, C.
    Rodrigues, F.
    Pereira, A.
    HAEMOPHILIA, 2022, 28 : 35 - 35
  • [37] A retrospective single-center study on the effectiveness and tolerability of emicizumab in patients with hemophilia a with and without inhibitors
    Ahmad, Sheikh Bilal
    Amin, Asifa
    Rohi, Malik
    Muzaffar, Sarwat
    Fahad, Sheikh
    EXPERT REVIEW OF HEMATOLOGY, 2025, 18 (03) : 275 - 281
  • [38] Cost-Effectiveness of Emicizumab Vs Efanesoctocog Alfa, Standard Half Life (SHL) and Other Extended Half Life (EHL) FVIII Products for Prophylaxis in People with Severe Hemophilia a without Inhibitors
    Curtis, Randall
    Decker-Palmer, Marquita
    Wilson, Michele R.
    McDade, Cheryl L.
    Lin, Chia-Wei
    Wallick, Chris
    Ko, Richard H.
    BLOOD, 2023, 142
  • [39] EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A AND INHIBITORS: A SYSTEMATIC REVIEW
    Camelo, R.
    Prudente, T. P.
    Minare, D. V.
    Gomes, G. D. P. V. C.
    Roberti, M. D. R. F.
    HAEMOPHILIA, 2023, 29 : 53 - 54
  • [40] Emicizumab prophylaxis overcomes factor VIII inhibitors in Hemophilia A
    Shima, Midori
    JOURNAL OF PEDIATRICS, 2017, 190 : 289 - 289
12345